EP0192935B1 - 3-Piperidinyl- 1H-Indazole, Verfahren zu deren Herstellung und deren Anwendung als Arzneimittel - Google Patents

3-Piperidinyl- 1H-Indazole, Verfahren zu deren Herstellung und deren Anwendung als Arzneimittel Download PDF

Info

Publication number
EP0192935B1
EP0192935B1 EP86100347A EP86100347A EP0192935B1 EP 0192935 B1 EP0192935 B1 EP 0192935B1 EP 86100347 A EP86100347 A EP 86100347A EP 86100347 A EP86100347 A EP 86100347A EP 0192935 B1 EP0192935 B1 EP 0192935B1
Authority
EP
European Patent Office
Prior art keywords
compound
alkyl
piperidine
indazol
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP86100347A
Other languages
English (en)
French (fr)
Other versions
EP0192935A1 (de
Inventor
Joseph T. Strupczewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Roussel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharmaceuticals Inc filed Critical Hoechst Roussel Pharmaceuticals Inc
Priority to AT86100347T priority Critical patent/ATE61054T1/de
Publication of EP0192935A1 publication Critical patent/EP0192935A1/de
Application granted granted Critical
Publication of EP0192935B1 publication Critical patent/EP0192935B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to novel 3-(piperidinyl)-1 H-indazoles of the formula I wherein
  • U.S.-A-4,355,037 relates to 3-(4-piperidyl)-1,2-benzisoxazoles which exhibit analgesic activity.
  • EP-A-0 127 167 relates to 3-(4-piperidinyl)-1,2-benzisothiazoles which show antipsychotic and analgesic activity.
  • alkyl refers to a straight or branched chain hydrocarbon radical containing no unsaturation and having 1 to 7 carbon atoms such as methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 1-pentyl, 2-pentyl, 3-hexyl, 4-heptyl;
  • alkenyl refers to a straight or branched chain hydrocarbon radical having one olefinic bond and containing 3 to 7 carbon atoms such as 2-propenyl, 2-butenyl, 3-pentenyl, 3-hexenyl, 3-heptenyl;
  • cycloalkyl refers to a saturated hydrocarbon group possessing at least one carbocyclic ring, the ring containing from 3 to 7 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl; the term "
  • alkanols examples are methanol, ethanol, 1- and 2-propanol, 1,2-dimethylethanol, hexanol.
  • alkoxy refers to a radical formed by removal of the hydrogen atom from the hydroxy function of an alkanol.
  • alkanols examples are methoxy, ethoxy, 1- and 2-propoxy, 1,2-dimethylethoxy, hexoxy.
  • alkanoic acid refers to a compound formed by combination of a carboxyl group with a hydrogen atom or alkyl group.
  • alkanoic acids are formic acid, acetic acid, propanoic acid, 2,2-dimethylacetic acid, hexanoic acid; the term “halogen” refers to a member of the family consisting of fluorine, chlorine, bromine or iodine.
  • alkanoyl refers to the radical formed by removal of the hydroxyl function from an alkanoic acid. Examples of alkanoyl groups are formyl, acetyl, propionyl, 2,2-dimethylacetyl, hexanoyl.
  • alkylene refers to a bivalent radical of the lower branched or unbranched group it is derived from having valence bonds from two terminal carbons thereof, e.g. ethylene ( -CH 2 -CH 2 -) , propylene ( -CH 2 CH 2 CH 2 -), isopropylene ( CH 2 -CH-CH 2 -).
  • optical antipodes and as the racemic forms thereof.
  • the optical antipode may be prepared from the corresponding racemic forms by standard optical resolution techniques, involving, for example, the separation of diastereomeric salts of those instant compounds characterized by the presence of a basic amino group and an optically active acid, or by the synthesis from optically active precursors.
  • the present invention comprehends all optical isomers and racemic forms thereof of the compounds disclosed and claimed herein.
  • the formulas of the compounds shown herein are intended to encompass all optical isomers of the compounds so depicted.
  • 1 H-Indazoles substituted at the 1-position by a C 1 -C 7 -alkyl group i.e. compounds of formula II wherein R 1 is C 1 -C 7 -alkyl
  • compounds of formula II wherein R 1 is C 1 -C 7 -alkyl can also be prepared by reducing a 1-(C 1 -C 7 )-alkanoyl-or 1-(C 1 -C 7 )-alkoxycarbonyl-3-(piperidinyl)-1H-indazole by an alkali metal aluminum hydride such as, for example, lithium aluminum hydride, in an ethereal solvent such as tetrahydrofuran, at the reflux temperature of the reaction medium.
  • an alkali metal aluminum hydride such as, for example, lithium aluminum hydride
  • 1H-Indazoles of formula I wherein R 1 and X are as defined above and R 6 is as previously defined are prepared from 1H-indazoles of formula II where R' is cyano, or from 1-substituted 1H-indazoles of formula III where R' is cyano and R 2 and X are as above, by reaction with an alcohol of the formula R 6 0H , typically in the presence of an alkali metal cyanide such as potassium cyanide. Ordinarily the reaction is conducted in the presence of alkali metal cyanide such as potassium cyanide and an excess amount of the alcohol R 6 0H , which also works as a reaction medium.
  • a typical reaction condition is refluxing the reaction mixture for several hours and then further continuing the reaction at ambient temperature for 10 - 20 hours.
  • the 1 H-indazole, above, where R' is cyano is reacted with an alcohol of the formula R 6 0H in the presence of (usually only catalytic amount) an alkalic metal alkoxide of formula MOR 6 where M is an alkali metal, preferably sodium.
  • an alkalic metal alkoxide of formula MOR 6 where M is an alkali metal, preferably sodium.
  • sodium metal is added to an excess amount of an alcohol of formula R 6 0H to form the sodium alkoxide of formula NaOR 6.
  • the cyano substituted 1 H-indazole II is added to the mixture and if necessary the mixture is heated slightly until a uniform solution is formed.
  • the 3-(piperidinyl)-1 H-indazoles of the present invention are useful for treating psychoses by virtue of their ability to elicit an antipsychotic response in mammals.
  • Antipsychotic activity is determined in the climbing mice assay by methods similar to those described by P. Protais et al., Psychopharmacol., 50, 1 (1976) and B. Costall, Eur.J. Pharmacol., 50 , 39 (1978).
  • Antipsychotic response is achieved when the present 3-(piperidinyl)-1 H-indazoles are administered to a subject requiring such treatment as an effective oral, parenteral or intravenous dose of from 0.01 to 50 mg/kg of body weight per day. A particularly preferred effective amount is about 25 mg/kg of body weight per day. It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted according to the individual need and the professional judgment of the person administering or supervising the administration of the aforesaid compound. It is to be further understood that the dosages set forth herein are exemplary only.
  • the 3-(piperidinyl)-1 H-indazoles of the present invention are also useful as analgetics due to their ability to alleviate pain in mammals.
  • the analgetic utility is demonstrated in the phenyl-p-quinone writhing assay in mice, a standard assay for analgesia [Proc. Soc. Exptl. Biol. Med., 95 , 729 (1957)].
  • Analgesia production is achieved when the present 3-(piperidinyl)-1 H-indazoles are administered to a subject requiring such treatment as an effective oral, parenteral or intravenous dose of from 0-01 to 100 mg/kg of body weight per day. A particularly effective amount is about 25 mg/kg of body weight per day. It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted according to the individual need and the professional judgment of the person administering or supervising the administration of the aforesaid compound. It is to be further understood that the dosages set forth herein are exemplary only.
  • the 3-(piperidinyl)-1 H indazoles of the present invention are also useful as antidepressants by virtue of their ability to elicit an antidepressant response in mammals.
  • the antidepressant activity is demonstrated in the tetrabenazine induced ptosis assay in mice [International Journal of Neuropharmacology, 8 , 72 (1969)], a standard assay for antidepressant activity.
  • Antidepressant response is achieved when the present 3-(piperidinyl) -1 H-indazoles are administered to a subject requiring such treatment as an effective oral, parenteral or intravenous dose of from 0.01 to 50 mg/kg of body weight per day. A particularly preferred effective amount is about 25 mg/kg of body weight per day. It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted according to the individual need and the professional judgment of the person administering or supervising the administration of the aforesaid compound. It is to be further understood that the dosages set forth herein are exemplary only.
  • the compounds of the invention are also useful as antihypertensive agents due to their ability to depress blood pressure in mammals.
  • Antihypertensive activity is measured in the spontaneous hypertensive rat by the indirect tail cuff method described in "Methods in Pharmacology," A. Schwartz, Ed., Vol. 1, Appleton-Century Crofts, New York, 1971, p. 135. In this procedure a group of five animals are treated orally for three days with the test compound in relation to the control group of the same number. The drop in blood pressure is measured on the third day following administration.
  • the antihypertensive activities of some of the compounds, expressed as mm decrease in mean arterial blood pressure are given below:
  • Blood pressure reduction is achieved when the compounds of the invention are administered to a subject requiring such treatment at an effective oral, parenteral or intravenous does of from 0.1 to 50 mg/kg of body weight per day.
  • a preferred effective dose within this range is from about 0.1 to 5 mg/kg of body weight per day.
  • a particularly preferred effective amount is about 1 mg/kg of body weight per day.
  • Effective amounts of the present invention may be administered to a subject by any one of various methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions.
  • the 3-(piperidinyl)-1 H-indazoles of the present invention while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of stability, convenience or crystallization, increased solubility.
  • Preferred pharmaceutically acceptable addition salts include salts of mineral acids, for example, hydrochloric acid, sulfuric acid or nitric acid, salts of monobasic carboxylic acids such as, for example, acetic acid or propionic acid, salts of dibasic carboxylic acids such as, for example, maleic acid or fumaric acid, and salts of tribasic carboxylic acids such as, for example, carboxysuccinic acid or citric acid.
  • Effective quantities of the compounds of the invention may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
  • the aforesaid compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers or chewing gums. These preparations should contain at least 0.5% of active compound, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of active compound in such composition is such that a suitable dosage will be obtained.
  • Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1.0-300 milligrams of the active compound.
  • the tablets, pills, capsules or troches may also contain the following ingredients: a binder such as microcrystalline cellulose, gum tragancanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel (R) or corn starch; a lubricant such as magnesium stearate or Sterote; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring may be added.
  • a binder such as microcrystalline cellulose, gum tragancanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel (R) or corn starch
  • a lubricant such as magnesium stearate or Sterote
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such as sucrose or sac
  • dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings.
  • tablets or pills may be coated with sugar, shellac, or other enteric coating agents.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
  • the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of active compound, but may be varied between 0.5 and about 50% of the weight thereof. The amount of active compounds in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound.
  • the solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents
  • antibacterial agents such as benzyl alcohol or methyl parabens
  • antioxidants such as ascorbic acid or sodium bisulfite
  • chelating agents such as ethylenediaminetetraacetic acid
  • Example 2 a A solution of 4-(6-fluoro-1H-indazol-3-yl)piperidine-1-carbonitrile (3.0 g. 0.012 mol) of Example 2 a, methanol (35 ml) and 25% sodium methoxide in methanol (2.5 ml) was stirred at ambient temperature for 16 hours. Most of the methanol was removed in vacuo and the residue diluted with water. The aqueous mixture was extracted with CH 2 CI 2 . The extract was washed (H 2 0), dried ( Na 2 S0 4 ) and the solvent evaporated to yield 3.0 g of a solid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (8)

1.
EP86100347A 1985-01-23 1986-01-13 3-Piperidinyl- 1H-Indazole, Verfahren zu deren Herstellung und deren Anwendung als Arzneimittel Expired - Lifetime EP0192935B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT86100347T ATE61054T1 (de) 1985-01-23 1986-01-13 3-piperidinyl- 1h-indazole, verfahren zu deren herstellung und deren anwendung als arzneimittel.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69419885A 1985-01-23 1985-01-23
US694198 1985-01-23

Publications (2)

Publication Number Publication Date
EP0192935A1 EP0192935A1 (de) 1986-09-03
EP0192935B1 true EP0192935B1 (de) 1991-02-27

Family

ID=24787823

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86100347A Expired - Lifetime EP0192935B1 (de) 1985-01-23 1986-01-13 3-Piperidinyl- 1H-Indazole, Verfahren zu deren Herstellung und deren Anwendung als Arzneimittel

Country Status (18)

Country Link
EP (1) EP0192935B1 (de)
JP (1) JPS61172875A (de)
KR (1) KR900002243B1 (de)
AR (1) AR241434A1 (de)
AT (1) ATE61054T1 (de)
AU (1) AU581726B2 (de)
CA (1) CA1287355C (de)
DE (1) DE3677609D1 (de)
DK (1) DK32886A (de)
ES (3) ES8705876A1 (de)
FI (1) FI82243C (de)
GR (1) GR860159B (de)
HU (1) HU196784B (de)
NO (1) NO164976C (de)
NZ (1) NZ214876A (de)
PH (1) PH22660A (de)
PT (1) PT81886B (de)
ZA (1) ZA86465B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
IL90879A0 (en) * 1988-09-02 1990-02-09 Janssen Pharmaceutica Nv 3-piperidinyl-indazole derivatives,their preparation and antihypertensive compositions containing them

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355037A (en) * 1981-11-12 1982-10-19 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidyl)-1,2-benzisoxales
EP0127167A2 (de) * 1983-05-31 1984-12-05 Hoechst-Roussel Pharmaceuticals Incorporated 3-(4-Piperidinyl)-1,2-benzisothiazole und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355037A (en) * 1981-11-12 1982-10-19 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidyl)-1,2-benzisoxales
EP0127167A2 (de) * 1983-05-31 1984-12-05 Hoechst-Roussel Pharmaceuticals Incorporated 3-(4-Piperidinyl)-1,2-benzisothiazole und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
ES557043A0 (es) 1988-07-16
JPS61172875A (ja) 1986-08-04
ES8800925A1 (es) 1987-12-01
KR860005809A (ko) 1986-08-13
NO164976C (no) 1990-12-05
DE3677609D1 (de) 1991-04-04
ES557044A0 (es) 1987-12-01
ES551063A0 (es) 1987-05-16
FI860287A0 (fi) 1986-01-21
DK32886D0 (da) 1986-01-22
NO860227L (no) 1986-07-24
EP0192935A1 (de) 1986-09-03
NO164976B (no) 1990-08-27
FI82243B (fi) 1990-10-31
GR860159B (en) 1986-05-19
AU581726B2 (en) 1989-03-02
DK32886A (da) 1986-07-24
HU196784B (en) 1989-01-30
ES8802510A1 (es) 1988-07-16
KR900002243B1 (ko) 1990-04-07
ZA86465B (en) 1986-09-24
FI82243C (fi) 1991-02-11
CA1287355C (en) 1991-08-06
AU5264086A (en) 1986-07-31
PH22660A (en) 1988-11-14
FI860287A (fi) 1986-07-24
ES8705876A1 (es) 1987-05-16
PT81886A (en) 1986-02-01
ATE61054T1 (de) 1991-03-15
AR241434A1 (es) 1992-07-31
NZ214876A (en) 1990-03-27
PT81886B (pt) 1988-05-27
HUT40104A (en) 1986-11-28

Similar Documents

Publication Publication Date Title
EP0127167B1 (de) 3-(4-Piperidinyl)-1,2-benzisothiazole und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
EP0135781B1 (de) 3-(Piperidinyl)- und 3-(Pyrrolidinyl)-1H-indazole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0959075B1 (de) Heteroaryl-Piperidine und Piperazine und ihre Anwendung als antipsychotisches und analgetisches Mittel
CA2017193C (en) N-(aryloxyalkyl)heteroarylpiperidines and-heteroarylpiperazines, a pro cess for their preparation and their use as medicaments
KR100385384B1 (ko) 트리사이클릭피라졸유도체,이의제조방법및이를포함하는약제학적조성물
EP0417653A1 (de) 3-(1-Substituierte-4-Piperazinyl)-1H-Indazole, Verfahren zu deren Herstellung und deren Anwendung als Arzneimittel
US4355037A (en) 3-(4-Piperidyl)-1,2-benzisoxales
US4988690A (en) 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof
FR2662696A2 (fr) Antagonistes de la serotonine, leur preparation et medicaments les contenant.
EP0511074A1 (de) Heterocyclische Derivate mit Anti-Serotonin-Aktivität, ihre Herstellung und sie enthaltende Arzneimitteln
US4363808A (en) N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines
US4408054A (en) Oximes of 4-benzoyl-piperidines
EP0192935B1 (de) 3-Piperidinyl- 1H-Indazole, Verfahren zu deren Herstellung und deren Anwendung als Arzneimittel
EP0091512A2 (de) 6-Fluor-3-(3-(1-heterocyclo)propyl)-1,2-benzisoxazole, Verfahren zu ihrer Herstellung, deren pharmazeutische Zusammensetzungen und ihre Verwendung als Arzneimittel
NO164899B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolylindolforbindelser.
JPH0825997B2 (ja) ３−アミノプロピルオキシフェニル誘導体、その製法およびそれらを含有する医薬組成物
US4810792A (en) Piperidine intermediates
US4528376A (en) 3-(4-Piperidyl)-1,2-benzisoxazoles
JP2753146B2 (ja) ビス−アザー二環式抗不安薬の製法および中間体
FR2661178A1 (fr) Derives de [(tetrahydro-1,2,3,4 isoquinoleinyl-2)methyl]-4 piperidinecarboxylates-1 d'alkyle, leur preparation et leur application en therapeutique.
US4408053A (en) (4-Piperidyl)-substituted phenyl ketones
US4469869A (en) 3-(4-Piperidinium)-1,2-benzisoxazoles
HU182470B (en) Process for preparing 6,7-benzomorphan derivatives
US4788201A (en) 3-methylenespiro (benzofuranpiperidines)
US4434174A (en) Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19861105

17Q First examination report despatched

Effective date: 19881021

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 61054

Country of ref document: AT

Date of ref document: 19910315

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 3677609

Country of ref document: DE

Date of ref document: 19910404

ET Fr: translation filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19911213

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19911216

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19911218

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19911219

Year of fee payment: 7

Ref country code: GB

Payment date: 19911219

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19911223

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19920107

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19920131

Year of fee payment: 7

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19920310

Year of fee payment: 7

EPTA Lu: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19930113

Ref country code: GB

Effective date: 19930113

Ref country code: AT

Effective date: 19930113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19930114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19930131

Ref country code: CH

Effective date: 19930131

Ref country code: BE

Effective date: 19930131

BERE Be: lapsed

Owner name: HOECHST-ROUSSEL PHARMACEUTICALS INC.

Effective date: 19930131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19930801

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19930113

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19930930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19931001

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 86100347.3

Effective date: 19930810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050113